Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.
Preliminary results from a Phase 1b/2 clinical trial evaluating the safety, pharmacokinetics, and efficacy of TYME-88 (SM-88) to treat recurrent, non-metastatic prostate cancer found that all eight enrolled patients, who did ... Read more
QIAGEN will begin marketing a test that Johns Hopkins University developed to detect whether advanced prostate cancer patients are failing to respond to the widely used therapies Zytiga (enzalutamide) and ... Read more
Although the anti-CTLA-4 agent Yervoy (ipilimumab) opens the door to more anti-tumor T-cells entering a prostate-cancer tumor, the treatment produces little patient benefit, a clinical trial indicates. Yerboy activates the ... Read more